 "Lupin Pharma")
Shares of pharmaceutical companies remained under pressure in monring deals on Friday, with most of the frontline stocks trading lower by over 2% on the BSE.
Sun Pharmaceutical Industries, Lupin, Aurobindo Pharma and Natco Pharma were down more than 3% each, while Wockhardt, Glenmark Pharmaceuticals, Indoco Remedies and Ajanta Pharma down between 2%-3% on the BSE.
At 09:57 AM, the S&P BSE Healthcare index was down nearly 2% as compared to 0.24% rise in the S&P BSE Sensex.
In past four trading sessions, the pharma index underperforming the market by falling 5.7% as United States Food and Drug Administration (USFDA) observations on Lupin’s plant is overhangs for pharma companies. The benchmark index reported a marginal 0.31% decline during the same period.
Lupin has dipped nearly 5% to Rs 1,598, its lowest level since July 29, 2015 on the BSE. The stock trading at close to its 52-week low of Rs 1,589 touched on May last year during intra-day trade.
In past four trading sessions, the share of drug maker has fallen 14% from Rs 1,869 after the company on Tuesday said that the United States Food and Drug Administration (USFDA) inspected Lupin’s Goa facility last week and cited 9 observations.
The observations are on aspects such as inadequacy and adherence to standard operating procedures and we are in the midst of putting together a response to address the USFDA’s observations, Lupin said on a clarification on news report.
Sun Pharmaceutical Industries, Lupin, Aurobindo Pharma and Natco Pharma were down more than 3% each, while Wockhardt, Glenmark Pharmaceuticals, Indoco Remedies and Ajanta Pharma down between 2%-3% on the BSE.
Read more from our special coverage on "PHARMA SECTOR"
At 09:57 AM, the S&P BSE Healthcare index was down nearly 2% as compared to 0.24% rise in the S&P BSE Sensex.
In past four trading sessions, the pharma index underperforming the market by falling 5.7% as United States Food and Drug Administration (USFDA) observations on Lupin’s plant is overhangs for pharma companies. The benchmark index reported a marginal 0.31% decline during the same period.
Lupin has dipped nearly 5% to Rs 1,598, its lowest level since July 29, 2015 on the BSE. The stock trading at close to its 52-week low of Rs 1,589 touched on May last year during intra-day trade.
In past four trading sessions, the share of drug maker has fallen 14% from Rs 1,869 after the company on Tuesday said that the United States Food and Drug Administration (USFDA) inspected Lupin’s Goa facility last week and cited 9 observations.
The observations are on aspects such as inadequacy and adherence to standard operating procedures and we are in the midst of putting together a response to address the USFDA’s observations, Lupin said on a clarification on news report.
| Name | 14/03/2016 | LTP | % chg |
| Lupin | 1868.50 | 1616.00 | -13.51 |
| Natco Pharma | 504.55 | 452.45 | -10.33 |
| Wockhardt | 994.60 | 930.00 | -6.50 |
| Sun Pharma | 864.00 | 809.65 | -6.29 |
| Sanofi India | 4427.45 | 4155.00 | -6.15 |
| Pfizer | 1760.80 | 1655.00 | -6.01 |
| Ajanta Pharma | 1416.75 | 1333.00 | -5.91 |
| Abbott India | 4866.75 | 4630.25 | -4.86 |
| Glenmark Pharma. | 830.85 | 791.15 | -4.78 |
| Divi's Lab. | 1011.60 | 970.75 | -4.04 |
| Dr Reddy's | 3234.35 | 3117.50 | -3.61 |
| Aurobindo Pharma | 735.10 | 709.00 | -3.55 |
| Strides Shasun | 1063.85 | 1030.60 | -3.13 |
| Cipla | 538.05 | 522.45 | -2.90 |
| Cadila Health. | 348.55 | 339.00 | -2.74 |
| Sensex | 24804 | 24803 | 0.0 |
| Healthcare index | 16024 | 15181 | -5.3 |
| LTP : Last traded price on BSE in Rs at 10:09 AM. | |||
